Postneoadjuvant Trastuzumab Deruxtecan Results in Higher Likelihood of iDFS Among Patients with HER2-positive EBC with Residual Invasive Disease After Neoadjuvant Treatment By Ogkologos - December 12, 2025 251 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the interim analysis of the DESTINY-Breast05 study Source RELATED ARTICLESMORE FROM AUTHOR ESMO Advocates for Equal Access to Optimal Cancer Care for all Patients with Cancer at the 79th World Health Assembly Daraxonrasib Shows Antitumour Activity Among Patients with Previously Treated RAS-mutated Pancreatic Ductal Adenocarcinoma FDA Approves Vepdegestrant for ER-positive, HER2-negative, ESR1-mutated Advanced or Metastatic Breast Cancer MOST POPULAR Five Questions With…Fern, Christina, Mary, and Shelley. May 26, 2022 Mathew Knowles, Father Of Beyoncé, Fought And Beat Breast Cancer November 5, 2019 Touching a nerve: How neuroscience could advance our understanding of cancer December 1, 2021 ESMO Clinical Practice Guideline Express Update on the adoption of physical... January 27, 2026 Load more HOT NEWS EMA Publishes Guidance to Provide Key Methods and Good Regulatory Practices... Melanoma Cells Are More Likely to Spread after a Stopover in... Safety, Tolerability and Antitumour Activity of Lorlatinib in Patients with ALK-Driven... The Risk of irAEs After Immune Checkpoint Inhibitor Therapy May Not...
